CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH Meaningful advances in sarcoma treatment have been painfully slow. Modern immunotherapy may change that. The article referenced by this editorial reports the results of CMB305 plus atezolizumab or atezolizumab alone in patients with NY-ESO-1–expressing synovial or myxoid round cell liposarcoma. The relevance of this study furthers the data using novel immunotherapeutic strategies, which generate B- and T-cell responses for two rare sarcomas that can serve as a foundation for future trials.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
